Showing results (1091-1100 of 4,514) with videos related to

Sort By:
Pageof 452
Future Oncology (London, England)|October 24, 2024
Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progressionJonathan Krell, Danielle Shaw, John McGrane, et al.
Future Oncology (London, England)|May 11, 2026
Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocolsNeal D Shore, Karim Fizazi, Michael Thomas Schweizer, et al.
Future Oncology (London, England)|May 11, 2026
Real-world treatment patterns for metastatic urothelial cancer in 5 European countries: EVEREST 2Maria De Santis, Neil Milloy, Maria Walley, et al.
Future Oncology (London, England)|May 22, 2026
Perceptions and lived experiences with abemaciclib and endocrine therapy for early breast cancer: a rapid communicationHelena Harder, Val Jenkins, Lesley Fallowfield
Future Oncology (London, England)|May 21, 2026
How I treat soft tissue sarcomaJavier Pozas, Niveditha Vasagiri, Ioanna Nixon, et al.
Future Oncology (London, England)|May 16, 2026
TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinomaMatthew D Galsky, Alexandra Drakaki, Arnab Basu, et al.
Future Oncology (London, England)|February 27, 2026
Operational efficiencies of using one vs multiple bispecific antibodies for diffuse large B-cell lymphoma and follicular lymphoma in the USTara Graff, Savreet Bains Chawla, Monika Jun, et al.
Future Oncology (London, England)|April 10, 2026
Early hematologic dynamics and their association with patient-reported symptom burden in breast cancer pharmacotherapy: a prospective cohort studyHenry Sutanto, Merlyna Savitri, Een Hendarsih, et al.
Future Oncology (London, England)|May 27, 2026
Sacituzumab govitecan in colorectal cancer: clinical evidence and future directionsLuisa Nader, Paula Hoffmeister-Wittmann, Georg Martin Haag, et al.
Future Oncology (London, England)|June 2, 2026
Denosumab versus bisphosphonates for the management of bone metastases originating from breast cancer: a systematic review and meta-analysisMarc Boutros, Guy Awad, Jean-Pierre Saad, et al.
Pageof 452